

## **PUBLICATION LIST:**

1. Shojaee S, Chan LN, **Buchner M**, Cazzaniga V, Geng H, Qui YH, vonMinden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. *Nat Med*. 2016 Apr;22(4):379-87
2. Shojaee S, Caeser R, **Buchner M**, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkenkin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, Müschen M. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. *Cancer Cell*. 2015 Jun 9. pii: S1535-6108(15)00184-1.
3. Chen Z\*, Seyedmehdi S\*, **Buchner M**, Geng H, Lee JW, Klemm L, Titz B, Graeber T, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh M, Jung JU, Coligan JE, Bolland S, Mak T, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M. Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia. *Nature*. 2015 May 21;521(7552):357-61.
4. **Buchner M**, Park E, Geng H, Klemm L, Schjerven H, Paietta E, Kopanja D, Raychaudhuri P, Müschen M. Identification of FOXM1 as therapeutic target in B cell lineage acute lymphoblastic leukemia. *Nat Commun*. 2015 Mar 10;6:6471.
5. **Buchner M**, Swaminathan S, Chen Z, Müschen M. Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. *Immunol Rev*. 2015 Jan;263(1):192-209.
6. **Buchner M**, Müschen M. Targeting the B cell receptor signaling pathway in B lymphoid malignancies. *Curr Opin Hematol*. 2014 Jul;21(4):341-9.
7. Dühren-von Minden M, Übelhart R, Schneider D, Wossning T, Bach MP, **Buchner M**, Hofmann D, Surova E, Follo M, Köhler F, Wardemann H, Zirlik K, Veelken H, Jumaa H. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. *Nature*. 2012 Sep 13;489(7415):309-12.
8. Leonhardt F, Zirlik K, **Buchner M**, Prinz G, Hechinger AK, Gerlach UV, Fisch P, Schmitt-Gräff A, Reichardt W, Zeiser R. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. *Leukemia*. 2012 Jul;26(7):1617-29.
9. Hilgendorf I, Eisele S, Remer I, Schmitz J, Zeschky K, Colberg C, Stachon P, Wolf D, Willecke F, **Buchner M**, Zirlik K, Ortiz-Rodriguez A, Lozhkin A, Hoppe N, von Zur Muehlen C, Zur Hausen A, Bode C, Zirlik A. The Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib Attenuates Inflammation and Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice. *Arterioscler Thromb Vasc Biol*. 2011 Sep;31(9):1991-9.
10. Warncke M, **Buchner M**, Thaller G, Doderio A, Pfeifer D, Veelken, H. Regulation of the specificity of T cell-mediated anti-idiotypic immunity by natural regulatory T cells. *Cancer Immunol Immunother*. 2011 Jan;60(1):49-60.
11. Catusse J, Leick M, **Buchner M**, Zirlik K, Burger M. Role of the atypical chemokine receptor CRAM in regulating CCL19 and CCR7 activities on lymphocytes. *Molec. Cancer*. 2010 Nov 22;9:297.
12. **Buchner M**, Baer C, Prinz G, et al. The microenvironment differentially impairs passive and active immunotherapy in Chronic Lymphocytic Leukemia - Potential therapeutic synergism of CXCR4 antagonists. *Br J Haematol*. 2010 Oct;151(2):167-78.

13. Stachon P, Missiou A, Walter C, Varo N, **Buchner M**, Zirlik K, Bode C, Zirlik A. Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis. *PLoS One*. 2010 Jul 14;5(7):e11589.
14. **Buchner M**, Baer C, Prinz G, et al. Spleen Tyrosine Kinase Inhibition Prevents Chemokine- and Integrin-Mediated Stromal Protective Effects in Chronic Lymphocytic Leukemia. *Blood*. 2010 Jun 3;115(22):4497-506.
15. **Buchner M**, Fuchs S, Prinz G, et al. Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. *Cancer Res*. 2009 Jul 1;69(13):5424-32.